Immix Biopharma Achieves 95% CR Rate in 20-Patient NEXICART-2 Trial
Immix Biopharma's NEXICART-2 trial in relapsed/refractory AL Amyloidosis achieved a 95% complete response rate (19 of 20 patients), with all responses reached within one year post-dosing and no relapses observed. Subsequently enrolled patients are MRD-negative at one month, and a Phase 3 trial is slated following late September 2026 update.
1. NEXICART-2 Interim Results
Immix Biopharma's NEXICART-2 trial in relapsed/refractory AL Amyloidosis achieved a 95% complete response rate (19 of 20 patients), with all four MRD-negative patients converting to CR and no relapses observed to date.
2. Follow-up and Next Steps
All complete responses were reached within one year post-dosing, and subsequently enrolled patients with available data are MRD-negative at one month. The next NEXICART-2 data update is expected late September 2026.
3. Planned Phase 3 Trial
These strong interim results support Immix Biopharma's plan to initiate a multi-center, randomized Phase 3 trial in newly diagnosed AL Amyloidosis patients as a potential frontline therapy with NXC-201.